Julien Mazières: Alectinib is the first ALK inhibitor to significantly improve DFS compared with CT

Julien Mazières: Alectinib is the first ALK inhibitor to significantly improve DFS compared with CT

Julien Mazières: Alectinib is the first ALK inhibitor to significantly improve DFS compared with CT

Julien Mazières: Alectinib is the first ALK inhibitor to significantly improve DFS compared with CT

Julien Mazières: Alectinib is the first ALK inhibitor to significantly improve DFS compared with CT

Julien Mazières: Alectinib is the first ALK inhibitor to significantly improve DFS compared with CT

Julien Mazières: Alectinib is the first ALK inhibitor to significantly improve DFS compared with CT

Julien Mazières: Alectinib is the first ALK inhibitor to significantly improve DFS compared with CT

cancer